The approval in the second-line EGFR- and MET-altered setting was based on results from the SACHI trial, which compared Orpathys and Tagrisso against chemo.

The company is developing treatments for autism and substance use disorders tailored to patient subgroups identified by clinico-genomic signatures.

NEW YORK – Bristol Myers Squibb on Friday said the US Food and Drug Administration approved label updates for its autologous CAR T-cell therapies Breyanzi (lisocabtagene maraleucel) and Abecma ...

NEW YORK – Allarity Therapeutics has begun dosing patients in a Phase II trial studying its dual PARP and WNT pathway inhibitor stenoparib in patients with advanced, recurrent, platinum-resistant or ...

NEW YORK – Politicians and healthcare administrators in Washington have recently spoken out against direct-to-consumer pharmaceutical advertising, but experts say the latest legislative attempt to ban ...

NEW YORK – Plus Therapeutics announced this week that it will relaunch the CNSide cerebrospinal fluid assay in the US this year, restoring access to a test for diagnosing and monitoring patients with ...

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

NEW YORK – A2 Biotherapeutics has treated the first solid tumor patient with its CAR T-cell therapy A2B395 in a Phase I/II clinical trial, the firm announced Thursday.. Agoura Hills, California-based ...